CytoMed Therapeutics Limited (GDTC) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
CytoMed Therapeutics Limited has successfully dosed the first patient in its groundbreaking Phase I clinical trial, ANGELICA, which explores the potential of allogeneic CAR-gamma delta T cell therapy for treating advanced cancers. This innovative approach aims to improve accessibility and reduce costs by using donor-derived cells, marking a significant milestone for the company. Investors may find this development intriguing as it could reshape the landscape of cancer treatment.
For further insights into GDTC stock, check out TipRanks’ Stock Analysis page.
